Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.
Last trade$34.82
Day change-$0.20 (-0.57%)
Day range$34.29 – $35.69
Volume58,712
Market cap$1.42B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.42B
Price / earnings
13.84×
Price / book
3.4×
Price / sales
0.92×
EV / sales
1.35×
EV / EBITDA
8.49×
Profitability
Earnings per share
$2.53
Return on assets
6.78%
Return on equity
24.59%
Dividend yield
1.37%
Liquidity and leverage
Debt / equity
1.76×
Current ratio
3.2×
Quick ratio
1.28×
Cash ratio
0.26×
Cash flow
Price / cash flow
16.58×
Price / free cash flow
65.61×
Free cash flow
$21.67M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PAHC, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$386.77M
$396.75M
$383.54M
$373.91M
$363.89M
$378.7M
$347.83M
$309.26M
Cost of revenue
$258.24M
$262.35M
$257.87M
$241.25M
$244.11M
$268.69M
$243.26M
$207.39M
Gross profit
$128.54M
$134.4M
$125.68M
$132.66M
$119.78M
$110.01M
$104.57M
$101.87M
Selling, general and administrative
$78.9M
$86.24M
$81.02M
$82.33M
$68.52M
$76.29M
$71.05M
$76.34M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$78.9M
$86.24M
$81.02M
$82.33M
$68.52M
$76.29M
$71.05M
$76.34M
Operating income
$49.64M
$48.16M
$44.65M
$50.33M
$51.26M
$33.72M
$33.52M
$25.53M
Interest expense
-$11.29M
-$10.18M
-$10.43M
$0
-$12.06M
-$8.61M
-$9.36M
$0
Income before taxes
$38.78M
$32.34M
$32.31M
$36.43M
$36.27M
$23.85M
$29.69M
$4.84M
Income taxes
$9.26M
$10.63M
$8.29M
$8.97M
$9.74M
$6.62M
$8.81M
$1.65M
Net income
$29.52M
$21.71M
$24.02M
$27.46M
$26.53M
$17.22M
$20.88M
$3.19M
Net income attributable to common shareholders
$29.52M
$21.71M
$24.02M
$27.46M
$26.53M
$17.22M
$20.88M
$3.19M
EBITDA
$63.22M
$61.5M
$57.1M
$63.22M
$64.09M
$46.13M
$46.13M
$37.11M
Basic earnings per share
$0.73
$0.54
$0.59
$0.68
$0.65
$0.42
$0.52
$0.08
Diluted earnings per share
$0.72
$0.53
$0.59
$0.67
$0.65
$0.42
$0.51
$0.08
Recent news
Company coverage with links to the original publishers.
Align Technology has gained 25.4% over the past year, outperforming the S&P 500, driven by Invisalign portfolio expansion into younger patients and complex cases, plus strategic DSO partnerships. However, the stock faces headwinds from currency volatility and intense competition from traditional braces and lower-priced clear aligner alternatives. The company holds a Zacks Rank #3 (Hold) with 2026 EPS estimates revised down 1.5% to $11.12.
Envista Holdings (NVST) has gained 24% over the past year, outperforming its industry, driven by international expansion, new product launches, and strong earnings beats. The company achieved 9% adjusted EBITDA growth and 25% EPS growth. However, fierce competition, weakness in China sales, and foreign exchange headwinds pose risks to future revenue and margin expansion.
Bruker Corporation (BRKR) is well-positioned for growth driven by strong diagnostics and biosystems revenue, favorable European demand, and a $140 million cost-savings target by 2026 aimed at expanding margins by 250-300 basis points. However, uneven U.S. academic demand, macroeconomic uncertainty, and trade policy volatility present headwinds. The stock carries a Zacks Rank #3 (Hold) rating with a 3.4% earnings yield.
Labcorp Holdings (LH) has surged 48.2% year-to-date, driven by expansion in specialty testing markets, AI and automation initiatives, and six consecutive quarters of margin expansion. However, currency headwinds, intense competition, and acquisition-related execution risks could limit future growth. The company maintains a Zacks Rank #3 (Hold) with a 5% earnings yield.
Phibro reported Q1 FY2027 net sales of $386.8 million, up 6% year-over-year, with strong growth in higher-margin segments like Mineral Nutrition (+17%) and Performance Products (+16%). However, poultry market softness pressured short-term demand as producer margins tightened. Management prioritizes reducing excess inventory to improve free cash flow and pay down debt, while expecting protein producer margins to recover as feed costs decline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.12 per share
Declared
Nov 3, 2026
Ex-dividend
Nov 25, 2026
Pay date
Dec 16, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 2, 2026
$0.12
Sep 23, 2026
recurring
Jun 3, 2026
$0.12
Jun 24, 2026
recurring
Mar 4, 2026
$0.12
Mar 25, 2026
recurring
Nov 26, 2025
$0.12
Dec 17, 2025
recurring
Sep 3, 2025
$0.12
Sep 24, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.